immuno-oncology
BMS doubles down on BridgeBio alliance on SHP2 drugs
Phil Taylor
BridgeBio Pharma, Bristol-Myers Squibb, immuno-oncology, Oncology, Opdivo, partnering, SHP2
0 Comment
News/ News/ News/ Oncology/ R&D
Roche’s TIGIT ambitions take another blow
Phil Taylor
immuno-oncology, Non-small cell lung cancer, Oncology, Roche, TIGIT, tiragolumab
0 Comment
News/ News/ News/ Oncology/ R&D
Nykode vaccine shows its worth in cervical cancer trial
Phil Taylor
cancer vaccine, cervical cancer, HPV, immuno-oncology, Nykode Therapeutics, Oncology, Vaccibody
0 Comment
Market Access/ News/ News/ News/ Oncology
AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer
Phil Taylor
AstraZeneca, biliary tract cancer, Imfinzi, immuno-oncology, Oncology
0 Comment
Market Access/ News/ News/ News/ Oncology
Kymriah is first CAR-T cleared for follicular lymphoma in EU
Phil Taylor
CAR-T therapies, cell therapy, Gilead Sciences, immuno-oncology, Kymriah, Novartis, Oncology, regulatory approval, Yescarta
0 Comment
4th Annual Cell Engager Summit | May 24-26 | Boston, MA
Rosie Andre
cell engager, immune-oncology therapeutics, immuno-oncology, IO therapeutics, T-cell
0 Comment
Learn from the pioneers of immunotherapy
News/ News/ News/ Oncology/ R&D
Gilead dives deeper into NK cell therapies with Dragonfly deal
Phil Taylor
Dragonfly, Gilead Sciences, immuno-oncology, natural killer cell, Oncology, partnering
0 Comment
Market Access/ News/ News/ News/ Oncology
FDA says no to two more China-developed cancer drugs
Phil Taylor
China, Coherus, fda, HutchMed, immuno-oncology, Oncology, regulatory
0 Comment